Multiple myeloma Car-Ts face a US grilling
The FDA highlights high death rates and questions overall survival for Carvykti and Abecma.
Deal analysis part three – the undecided
Of the big oncology deals since 2016, there are still plenty that could go either way.
Deal analysis part two – the good
A look at big oncology deals since 2016 finds outright success stories hard to come by.
Mesothelin lives on
Work targeting mesothelin, and some other antigens that have hitherto disappointed, continues.
Lack of overall survival doesn't stop Flaura2
Approval on the basis of Flaura2 is part of a double success for Astra's Tagrisso, which has also scored in Laura.
Make or break time for Iovance
Lifileucel heads up the list of upcoming US FDA catalysts.
